Invesco
VTGN icon

Invesco’s VistaGen Therapeutics VTGN Stock Holding History

Invesco’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,557
Closed -$9.57K – 3955
2023
Q1 		$9.57K Buy
2,557
+300
+13% +$1.57K ﹤0.01% 3841
2022
Q4 		$6.97K Hold
2,257
– – ﹤0.01% 4005
2022
Q3 		$10K Buy
2,257
+13
+0.6% +$129 ﹤0.01% 3976
2022
Q2 		$59K Buy
2,244
+55
+3% +$1.94K ﹤0.01% 3954
2022
Q1 		$81K Buy
2,189
+24
+1% +$1.05K ﹤0.01% 3884
2021
Q4 		$127K Sell
2,165
-1,602
-43% -$104K ﹤0.01% 3870
2021
Q3 		$309K Buy
3,767
+915
+32% +$79.5K ﹤0.01% 3641
2021
Q2 		$270K Buy
+2,852
New +$211K ﹤0.01% 3675

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco's VTGN Position: Q2 2023 in Review

Invesco sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 2,557 shares — an estimated $9.57K sold.

Invesco first reported a position in VTGN in Q2 2021 and held it in 8 quarters. The position peaked at $309K in Q3 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Invesco reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Invesco sold 2,557 VistaGen Therapeutics shares in Q2 2023, an estimated $9.57K.
  • Invesco first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 8 quarters.
  • Invesco's VistaGen Therapeutics position peaked at $309K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Invesco's 13F filing for Q2 2023, filed 11 Aug 2023.